A significant collaboration between pharmaceutical giant Bristol Myers Squibb (BMS) and biotechnology company Evotec has been extended and expanded, bringing renewed focus and substantial investment to the field of neurodegenerative diseases. This partnership, which received a $50 million upfront payment from BMS to Evotec, could have far-reaching implications for conditions like inherited retinal diseases (IRDs) that share underlying neurodegenerative mechanisms.
Why This Matters to the IRD Community
While inherited retinal diseases primarily affect vision, many are characterized by the progressive degeneration of photoreceptor cells and other neurons in the retina. This cellular loss is a form of neurodegeneration, similar in principle to what occurs in diseases like Alzheimer's or Parkinson's. Therefore, advancements in understanding and treating neurodegenerative processes, even if initially focused on other conditions, can often provide valuable insights and potential therapeutic strategies applicable to IRDs. The extended partnership aims to discover disease-modifying treatments, which is a critical need across the spectrum of neurodegenerative conditions, including those impacting the retina.
Key Details of the Collaboration
The collaboration between Evotec and BMS (which acquired Celgene, the original partner) began in 2016 with the goal of identifying disease-modifying treatments for a wide range of neurodegenerative diseases.
This partnership has been described as